AstraZeneca announced (Oct. 30) the start of the Phase III Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company’s global biologics research and development arm. The goal of CALIMA, the first study in the Windward programme, is to determine whether benralizumab reduces the number of exacerbations in patients […]
severe asthma
October 30, 2013 |
Engage us on Facebook
Follow us on Twitter
Tweets by @mymcmedia